C1 esterase inhibitor (Human, CSL Behring)

N/A

Report date: 2022/02/14 15:39:27

Base Information

Drug NameC1 esterase inhibitor (Human, CSL Behring)
Drug Alias NameComplement C1 inactivatorC1酯酶抑制剂补充C1抑制蛋白C1 inaktivator HSBerinert P +[20] 
ClassificationBiologics > Blood components
Mechanisms of ActionSerine protease inhibitorsComplement C1s inhibitorsComplement C1r inhibitors
TargetsSerine proteaseComplement C1sComplement C1r
Therapy Area/IndicationsRejection of renal transplantationHereditary Angioedema Types I and IIAngioedemas, Hereditary
Global Approved IndicationsAngioedemas, Hereditary
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date1990/06/29
Country/TerritoryCzechiaBulgariaCanada +[18] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesCsl Behring Llc
China Registration ClassN/A

Develop Information

Active CompaniesCsl Behring LlcNational Institute Of Allergy And Infectious Diseases (Niaid)
Inactive CompaniesCsl Behring
Active IndicationsRejection of renal transplantationAngioedemas, Hereditary
Inactive IndicationsHereditary Angioedema Types I and II

Other Information

ATC CodeB06AC01
Related LinksN/A